title: Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure.
abstract: Heart failure (HF) and atrial fibrillation (AF) frequently coexist and share a reciprocal relationship. The presence of AF increases the propensity to HF and can worsen its severity as well as escalating the risk of stroke. Despite the proven efficacy of vitamin K antagonists and warfarin for stroke prevention in AF, their use is beset by numerous problems. These include their slow onset and offset of action, unpredictability of response, the need for frequent coagulant monitoring and serious concerns around the increased risks of intracranial and major bleeding. Three recently approved novel anticoagulants (dabigatran, rivaroxaban and apixaban) are already challenging warfarin use in AF. They have a predictable therapeutic response and a wide therapeutic range and do not necessitate coagulation monitoring. In this article, the relationship between HF and AF and the mechanisms for their compounded stroke risk are reviewed. The evidence to support the use of these three NOACs amongst patients with AF and HF is further explored.
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Boos
authors.forename: Michael
authors.initials: M
authors.lastname: Nam
authors.forename: A J
authors.initials: AJ
authors.lastname: Camm
mesh_terms: D000925:Anticoagulants / Q000494:pharmacology*; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D001562:Benzimidazoles / Q000494:pharmacology; D002908:Chronic Disease; D000069604:Dabigatran; D016903:Drug Monitoring; D006333:Heart Failure / Q000150:complications / Q000503:physiopathology; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D009025:Morpholines / Q000494:pharmacology; D017063:Outcome Assessment, Health Care; D011720:Pyrazoles / Q000494:pharmacology; D011728:Pyridones / Q000494:pharmacology; D018570:Risk Assessment; D000069552:Rivaroxaban; D012720:Severity of Illness Index; D020521:Stroke / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D013876:Thiophenes / Q000494:pharmacology; D014859:Warfarin / Q000494:pharmacology; D015091:beta-Alanine / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D009025:Morpholines; D011720:Pyrazoles; D011728:Pyridones; D013876:Thiophenes; D015091:beta-Alanine; C522181:apixaban; D014859:Warfarin; D000069552:Rivaroxaban; D000069604:Dabigatran